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Abstract 
Live vaccines are widely used in the avian industry. Such vaccines can be either injected or delivered on animal 
mucosa and are usually not adjuvanted. In this study we show that live vaccines efficacy can be improved by 
formulation with adjuvants in a model of mucosal delivery of live infectious bronchitis vaccine in chicken. Three 
adjuvant technologies have been tested using intranasal and spray delivery methods to poultry. Those technologies 
are water in oil in water emulsion, nanoparticles and polymer adjuvants. Intranasal delivery of polymer and 
nanoparticles adjuvanted live vaccines improved significantly the antibody titer and protection to challenge observed 
compared to a commercial non-adjuvanted reference. Moreover, spray delivery of the polymer adjuvanted vaccine 
showed a significantly higher protection compared to the non-adjuvanted reference. Our data demonstrates that the 
use of MontanideTM adjuvants in the formulation of live poultry vaccines for mucosal delivery can confer to 
vaccinated animals a significantly improved protection against pathogens. 
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1. Introduction 
 
Live vaccines are widely employed in veterinary practice. Generally used to vaccinate young animals 
[1], these types of vaccines are dedicated to a large spectrum of species with applications from farm 
animals such as pigs [2] or poultry [3] to companion animals such as horses [4] or pets [5]. Based on the 
infectious properties of the attenuated or genetically modified live micro-organism, these types of 
vaccines exist for bacterial [6], viral [7] and parasitic [8] pathogen models. The live pathogens delivered 
by vaccine inoculums are thought to initiate both humoral and cellular protective response after one 
delivery. Under experimental conditions, 100% efficacy has been demonstrated for live vaccine 
application. However, in field practice up to 10% of vaccinated animals present a lack of protection after 
live vaccine delivery [1]. This population represents a reservoir for pathogens and creates potential for 
new pathogenic strains to appear and challenge the vaccine strain in terms of herd protection. Live 
vaccines can also have an impact on the economical performance of herds as they will induce a transient 
infection necessary to trigger the immune response, and as reversions to virulence have already been 
observed in the field. Finally, whereas the cost of bacterial or viral vaccine production can be very low, 
the vaccine strains of parasitic pathogens can be very expensive to maintain and produce. Improvement of 
the safety and efficacy of live vaccines is therefore an important issue.  
 
Several improvements are expected from the addition of adjuvants in live vaccine formulations. The 
most important would be a reduction of the antigenic dose delivered, which would lead to safety 
improvements, cost limitations and a better control of risks linked to the vaccination procedure. Adjuvant 
benefits in relation to this type of vaccine technology have already been demonstrated with model 
adjuvant molecules [9]. However, laboratory studies adjuvants are hardly compatible with industrial-scale 
production. On the contrary, the Montanide™ range of adjuvants is a well established brand of vaccine 
adjuvants [10] which is already used in all farm animal models at industrial scale in combination with 
diverse types of antigens. In this study we assessed the efficacy and safety of MontanideTM adjuvanted 
mucosal live infectious bronchitis (IB) vaccines in poultry. 
 
IB virus is a coronavirus that affects airways, digestive system, kidneys and reproductive system in 
poultry [11]. Commercial live vaccines against IB are widely used in chicken breeding. We chose this 
model to study the effect of 3 families of adjuvants on the improvement of an IB commercial live vaccine 
in chicken delivered by individual intranasal or collective spray methods. Montanide™ ISA 201 VG (ISA 
201) is a double water in oil in water emulsion that is an effective adjuvant for injectable vaccines in 
chicken [12], Montanide™ Gel 01 ST (Gel 01) is a polymer based adjuvant and Montanide™ IMS 1313 
N VG (IMS 1313 N) consists of nanoparticles in an aqueous phase containing an immunostimulating 
compound. The adjuvants were used as extemporaneous diluents for the lyophilized IB antigen. We could 
show that Gel 01 and IMS 1313 N adjuvanted formulations improved significantly the antibody titers and 
protection provided by intranasal delivery of live commercial IB vaccine, whereas only the polymer 
adjuvanted vaccines showed a significantly better efficacy compared to the commercial reference in the 
spray assay. 
 
2. Material and Methods 
 
2.1. Animals 
Trial 1: One day old SPF (specific pathogen free) chickens were purchased at Lohmann Tierzucht 
(Germany). Animals were seronegative to infectious bronchitis virus at day 0. 10 animals were included 
in each vaccine and control group.  
Trial 2: 22 days old chickens of the egg cross Highsex Brown. 10 animals were included in each 
vaccine and control group. 
All protocols were validated by internal ARRIAH’s ethics comity prior to launch according to OIE 
recommendations. 
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2.2. Antigen 
The antigen used was IB virus strain H-120 from SPF egg embryos (ARRIAH). Vaccine antigen titer 
was log 4.0 egg infective dose 50 (EID50) per vaccine dose for trial 1 and log 7.0 EID50 per vaccine dose 
for trial 2. All adjuvanted test vaccines and the commercial non-adjuvanted positive control contained the 
same amount of antigen per dose delivered to chickens. 
 
2.3. Adjuvants  
Montanide™ IMS 1313 N VG (IMS 1313 N), Montanide™ ISA 201 VG (ISA 201) and Montanide™ 
Gel 01 (Gel 01) were used in this study. 
Montanide™ IMS is a ready to dilute range of adjuvants consisting of liquid particles (10-500 nm) 
dispersed in an aqueous phase containing an immunostimulating compound. Montanide™ ISA is a ready 
to use range of oil adjuvants that can be used to manufacture different types of emulsions. ISA 201 allows 
the formulation of water-in-oil-in-water vaccines. Montanide™ Gel 01 is a ready to dilute polymeric 
adjuvant. It contains gel particles of sodium polyacrylate in water. 
  
2.4. Vaccine formulations 
All adjuvants were formulated extemporary to vaccination.  
 
Adjuvant Type of adjuvant Adjuvant Ratio (weight)  Formulation process 
IMS 1313 N  Nanoparticles 50% Manual shaking 
ISA 201 Water in oil in water 
emulsion 
50% Specific procedure 
(available on request) 
Gel 01 Polymer 10% Manual shaking 
 
A commercial live IB vaccine (strain H-120) produced by FGI ‘ARRIAH’, Russia (batch 211, control 
211) was used as a positive control; this vaccine does not contain any adjuvant. 
 
2.5. Vaccination and Experimental groups 
In trial 1, 90 chickens were randomly separated in 9 groups of 10 chickens.  
In groups 1 to 4, animals were vaccinated by intranasal delivery (IN) with the corresponding group test 
vaccine (i.e. IMS 1313 N adjuvanted vaccine, ISA 201 adjuvanted vaccine, Gel 01 adjuvanted vaccine or 
commercial non-adjuvanted control). Each animal received 1 antigen dose in 0.1 ml injected evenly in 
both nostrils.  
In groups 5 to 8, animals were vaccinated by the spray method with the corresponding group vaccine 
(i.e. IMS 1313 N adjuvanted vaccine, ISA 201 adjuvanted vaccine, Gel 01 adjuvanted vaccine or 
commercial non-adjuvanted control). For each group, 2.5 cm3 of solution containing 10 doses of vaccine 
were sprayed over 10 animals in a box. Spray procedure was performed upon a high volume but the 
average of antigen dose received by the 10 vaccinated chickens was identical to the individual IN 
vaccination procedure dose. Group 9 (negative control) was left unvaccinated. 
In trial 2, 50 chickens were randomly separated in 5 groups of 10 chickens. 
In groups 1 to 4, animals were vaccinated by intranasal delivery (IN) with the corresponding group test 
vaccine (i.e. IMS 1313 N adjuvanted vaccine, ISA 201 adjuvanted vaccine, Gel 01 adjuvanted vaccine or 
commercial non-adjuvanted control). Each animal received 1 antigen dose in 0.1 ml injected evenly in 
both nostrils. Group 5 (negative control) was left unvaccinated. 
 
2.6. Safety 
For each trial, animal behavior was followed before and after vaccine delivery in order to identify any 
modification related to the vaccination procedure. 
 
2.7. Serology 
In both trials, blood samplings were performed at day 0, 7, 14, 21, 28, 35, 42, 49 and 56. Antigen 
specific antibodies were detected individually at each date by antigen specific ELISA (Enzyme Linked 
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Immunosorbent Assay). ELISA procedure was performed according to the manufacturer’s protocol. (IB 
antibody detection kit: ProFLOK® IBV ELISA, Synbiotics, Lyon, France). 
 
2.8. Challenge 
In both trials, an infectious challenge procedure was performed at day 56 by delivery of 0.1ml in each 
nostril of a highly virulent IB virus strain (M-41; titer: log 5.0 EID50 per ml in trial 1, log 7.0 EID50 per ml 
in trial 2). After challenge procedure, animals were observed over ten days post infection for IB specific 
clinical signs presence. 
In trial 2 the strength and duration of clinical signs were followed after challenge. Briefly, the duration 
of illness was assessed by counting the animals presenting IB clinical signs. The strength of the infection 
was assessed by scoring for typical clinical signs as described by J.W. Macdonald [13]. Intensity of 
clinical symptoms was graduated as follows: short-breathed – 1 point; apparent short-breathed, tracheal 
rattle – 2 points; symptoms of respiratory failure, suppression, discharge from nostrils, tumescence of the 
head, rattles – 3 points. The sum of individual score was used to define a group scoring relative to the 
clinical signs intensity. 
 
2.9. Statistics   
Statistical analysis was performed using Student’s t tests and proportion tests. Results were considered 
as significantly different when P≤0.05. 
 
3. Results 
 
In order to assess the safety and efficacy of MontanideTM adjuvanted mucosal IB live vaccines, 8 
groups of 10 1-day old SPF chickens were vaccinated with Montanide ISA 201 VG, Montanide IMS 1313 
N VG, Montanide Gel 01 ST or commercial non-adjuvanted IB formulations by mucosal delivery, either 
via individual intranasal delivery or by multi-animals spray delivery (Trial 1). One negative control group 
was left unvaccinated. A kinetic of blood sampling was performed to assess the immune response and 
antigen titers were measured via antigen specific IgG ELISA. All animals from all groups were submitted 
to an IB challenge at day 56. 
 
To confirm the potential of adjuvants for live vaccines in field conditions, the same protocol was 
applied to 5 groups of 10 22-day old farm chickens via intranasal delivery (Trial 2). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Trial 1. Efficacy of intranasal delivery of adjuvanted live IB vaccines. (a) Antibody titers (log scale) from 
day 7 to day 56 post vaccination. (b) Protection to challenge: animals without symptoms observed for 10 days after 
challenge. (* indicate significant differences compared to the commercial reference). The control group is the non-
vaccinated group.  
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Figure 2: Trial 1. Efficacy of spray delivery of adjuvanted live IB vaccines. (a) Antibody titers (log scale) from day 7 
to day 56 post vaccination. (b) Protection to challenge: animals without symptoms were counted for 10 days after 
challenge. (* indicate significant differences compared to the commercial reference). Control stands for the non-
vaccinated group.  
 
3.1. Trials 1 and 2: General tolerance to the adjuvanted formulations 
No modification of animal behavior (social, movements, feeding) could be observed after vaccine 
delivery in any of the protocols. Furthermore, no IB specific clinical signs could be observed after 
vaccine delivery. At last, no local reactions on the mucosa (eye, nostril, mouth) to vaccine delivery could 
be observed after IN or spray vaccination. 
 
3.2. Trial 1: Efficacy of spray and IN delivery of IB adjuvanted vaccine in SPF chickens. 
Using IN delivery, Gel 01 and IMS 1313 N adjuvanted vaccines were able to trigger a significantly 
stronger humoral immune response than the non-adjuvanted commercial reference (Figure 1a). IMS 1313 
N group showed a faster response than the non-adjuvanted reference. Antibody titers of the ISA 201 
vaccinated group were higher but not significantly different from the commercial control. After challenge, 
unvaccinated animals all showed clinical signs specific of IB infection as soon as 6 days post infection 
(Figure 1b). Gel 01 and IMS 1313 N adjuvanted vaccines conferred an improved protection to the 
vaccinated animals compared to the commercial reference (Figure 1b). 
 
Spray delivery was not as efficient as IN delivery. Antibodies titers obtained after spray vaccination 
were lower than the IN induced titers for all groups. No adjuvanted group showed significant 
improvements compared to the commercial formulation (Figure 2a). A faster onset of the response could 
still be observed (as soon as day 14 for adjuvanted vaccines, at day 21 for the commercial formulation). 
After challenge, the Montanide™ Gel 01 based formula was the only formula able to induce a high rate of 
protection when used in spray (88% of animals without symptoms at day 10 post challenge, figure 2b) 
and to have a significantly higher efficacy than the commercial formulation (<15% of protection at day 10 
post challenge). 
 
3.3. Trial 2: Efficacy of IN delivery of IB adjuvanted vaccine in farm chickens. 
In 22 days old farm chicken, individual IN delivery of all MontanideTM adjuvanted vaccines was able 
to trigger a significantly stronger humoral immune response than the non-adjuvanted commercial 
reference (Figure 3). 
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Figure 3: Trial 2. Efficacy of intranasal delivery of adjuvanted live IB vaccines in 22d old farm chickens: Antibody 
titers (log scale) from day 0 (before vaccination) to day 56 after vaccination (* indicate significant differences 
compared to the commercial reference). Control stands for the non-vaccinated group.  
 
 
Vaccine Average point per 
chicken 
Average duration 
of illness (days) 
Percentage of sick 
animals 10 days 
post challenge 
ISA 201  0,50±0,70 1,00±0,71 40 
Gel 01 0,30±0,48 0,30±0,48 50 
IMS 1313 N 0,20±0,42 0,20±0,42 30 
Commercial reference 2,44±1,94 2,33±1,73 89 
Unvaccinated control 9,08±1,83 6,92±1,44 100 
Table 1: Protection to challenge: animals were observed and scored for 10 days post challenge.  
 
In trial 2, clinical symptoms after challenge were scored following J.W. Macdonald [13]. All the 
unvaccinated animals presented clinical signs at a high score. The commercial vaccine formulations 
reduce the scoring but 89% of the animals were still positive for clinical signs at day 10 post challenge. 
The scoring per group was strongly reduced for all adjuvanted vaccine groups. Illness duration was also 
reduced to less than one day when using Montanide™ adjuvants while unvaccinated controls were sick 
for almost a week on average and chickens receiving the commercial formulation for 2-3 days (Table 1). 
 
4. Discussion 
 
New tools are increasingly needed to manage the biosafety of avian production regarding viral and 
bacterial diseases. Indeed, viral diseases can cause zoonotic risks, and bacterial diseases may become 
difficult to control due to the recent evolution of regulation toward stronger restrictions on antibiotic use. 
Vaccination is one of the most powerful tools to save the farming efficiency and improve the protection 
of herds [14]. However, it is not possible to add multiple injection vaccination steps in avian farming 
procedures due to the cost and time consumed by such steps in farms containing several thousands of 
animals. Mucosal spray vaccination could then be a very useful tool for time and cost efficient 
vaccination of large groups of animals [15].  
days 
* 
  * * 
* * *  *  * 
 *  * 
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We have shown previously that nanoparticles vaccine adjuvants can enhance the efficacy of avian 
mucosal vaccination against parasitic disease [16, 17]. In this study we have demonstrated that following 
individual intranasal delivery of adjuvanted formulations containing live viral vaccines, nanoparticles or 
polymer based adjuvant technologies were able to improve the immune response and protection to IB 
challenge. Both Montanide™ Gel 01 ST and Montanide™ IMS 1313 N VG adjuvants conferred a 
significantly enhanced protection to challenge compared to the non-adjuvanted commercial reference, in 
SPF and farm chickens. Montanide™ ISA 201 VG is a mineral oil adjuvant used for the formulation of  
water in oil in water emulsion vaccines that can be used for injectable delivery in chicken [12]. Mineral 
oil based adjuvants are a reference for commercial injectable poultry vaccines, and we thought that the 
use of an oil emulsion vaccine with an aqueous continuous phase such as ISA 201 VG could be a good 
vector for mucosal delivery and enhance the efficacy of mucosal vaccines. However, we show in this 
study that nanoparticles and polymer adjuvants give much better results for mucosal delivery in poultry. 
 
Using spray delivery, the polymer based adjuvant was the only adjuvant formulation able to confer 
protection at a very high rate and to be significantly more efficient that the commercial formulation. This 
study shows that Montanide™ Gel 01 ST can enhance the efficacy of mass spray delivery of live viral 
vaccines. Spray parameters such as particle size can have an impact on spray vaccination and may explain 
the poor performance of IMS 1313 N in spray delivery. These parameters were not controlled here and 
should be optimized in further studies. Particle sizing was previously shown to be important in the 
antigen/immune system contact and to have and impact on the immune response [18, 19]. Further studies 
should also assess if the protective stimulation using spray vaccination that we observed using polymer 
adjuvanted vaccine was restricted to the nasal mucosa or was also linked to the oral and on eye surfaces 
which would lead to different immune system / antigen contact [20]. Other criteria still remain to be 
studied, such as the ability to manage the antigen load or to combine several antigens in the same spray 
vaccine. 
 
Benefits anticipated from the use of adjuvants in live vaccines concern both safety and efficacy 
improvements. The use of adjuvants in live vaccine could improve the efficacy and lead to a better 
management of the antigen load per vaccine dose. Such efficacy improvement could also improve the 
safety of the vaccine as the possible adverse reactions observed after delivery of live infectious vaccines 
could be lowered. Moreover, the risk of reversion to virulence that has already been observed in avian 
species would also be reduced [21, 22]. Moreover, the use of adjuvants should reduce the number of low 
or not responding animals and therefore reduce the possible reservoir for the disease [1]. Adjuvanted 
vaccine performance could also compensate the decrease of antigenic load in case of impaired vaccine 
delivery or formulation, a possible viricidal effect of storage or inappropriate resuspending conditions. 
Finally, it would be interesting to study whether adjuvants such as polymer formulae can also improve the 
survival and transmission of live vaccines.  
 
Our work underlines the ability to use polymer adjuvants in mass vaccination for avian species, 
opening doors to improvements of live avian vaccines safety and efficacy. 
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